Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

CTI Molecular Imaging, Inc.: Positron emission tomography equipment supplier goes public June 21 via initial offering of 10.7 mil. shares of common stock at $17 each. Ten mil. shares were offered by the company plus 720,000 shares from selling shareholders. Estimated proceeds to the Knoxville, Tennessee firm of about $156 mil. will be used to expand manufacturing facilities, grow the firm's PETNet distribution network, repay debt and cover general corporate expenses. CTI, which reported 2001 sales of $189 mil., up 52%, announced plans for the offering in April (1"The Gray Sheet" April 29, 2002, p. 18). Offering managers include Credit Suisse First Boston, U.S. Bancorp Piper Jaffray, Bear Stearns, Banc of America Securities and Wachovia Securities. The underwriters hold an overallotment option for about 1.6 mil. additional shares...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel